SETD2 and nonpapillary renal cell carcinoma: For clinical translation, pharmaceutical investigation of the cross-talks between SETD2 and lipids metabolism especially SM may provide enlightenments for preventing tumorigenesis in PKD patients and ccRCC therapy.